Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

New Experimental Treatment for Prostate Cancer Revealed at AACR

SDX AACR 2023 poster 05Apr 2023.pptx

PRESS RELEASE • APR 14, 2023 08:00 EDT

Evexomostat (SDX-7320) shows potent anti-tumor effects in pre-clinical models of prostate cancer, including castration-resistant. New research data to be presented at AACR 2023 in Orlando, FL

Get in touch with us.

We'd like to hear from you.

If you'd like information on metabo-oncology, our clinical trials, our team or anything else SynDevRx-related, we welcome your inquiries.